NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Hits New 12-Month High - Here's What Happened

Key Points

• Shares hit a new 52-week high, trading as high as $7.30 (last $6.75) on volume of 937,413 shares versus a prior close of $5.87, signaling a sharp intraday move.
• The stock is trading well above its technical averages (50‑day $2.39, 200‑day $1.63) and has a market capitalization of $850.57 million, though it shows a negative P/E (-0.68) and low beta (0.09).
• NovaBay is a clinical‑stage biotech using its Aganocide® Technology to develop non‑antibiotic anti‑infectives and sells commercial products including Avenova® (eyelid cleanser) and NeutroPhase® (wound/skin cleanser).

Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $7.30 and last traded at $6.75, with a volume of 937413 shares trading hands. The stock had previously closed at $5.87.

NovaBay Pharmaceuticals Price Performance

The business's 50-day moving average is $2.39 and its 200 day moving average is $1.63. The firm has a market capitalization of $850.57 million, a P/E ratio of -0.68 and a beta of 0.09.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. C2C Wealth Management LLC lifted its position in NovaBay Pharmaceuticals by 78.2% during the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 43,000 shares during the period. Apollon Wealth Management LLC acquired a new position in shares of NovaBay Pharmaceuticals in the 3rd quarter valued at approximately $35,000. Finally, Ground Swell Capital LLC bought a new stake in shares of NovaBay Pharmaceuticals during the 3rd quarter worth approximately $25,000. Institutional investors own 23.25% of the company's stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company's synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay's research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company's primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.